Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 18/20 | 0.69 |
| ▸ | DRD2 | P14416 | 18/20 | 0.69 |
| ▸ | HTR2A | P28223 | 17/20 | 0.69 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.51 |
| ▸ | DRD4 | P21917 | 1/20 | 0.51 |
| ▸ | HTR2C | P28335 | 1/20 | 0.51 |
| ▸ | HTR7 | P34969 | 1/20 | 0.51 |
| ▸ | DRD3 | P35462 | 1/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.47 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5472528 | 0.86 | HTR1A (0.55) | HTR1ADRD2HTR2ASLC6A4DRD4 | |
| SCHEMBL5472531 | 0.86 | HTR1A (0.55) | HTR1ADRD2HTR2ASLC6A4DRD4 | |
| SCHEMBL5472522 | 0.86 | HTR1A (0.55) | HTR1ADRD2HTR2ASLC6A4DRD4 | |
| SCHEMBL18918650 | 0.82 | DRD2 (1.00) | HTR1ADRD2HTR2A | |
| SCHEMBL5467141 | 0.80 | HTR1A (0.54) | HTR1ADRD2HTR2ASLC6A4DRD4 | |
| SCHEMBL5470505 | 0.80 | GRIN2B (0.53) | HTR1ADRD2HTR2ADRD4HTR2C | |
| SCHEMBL8409485 | 0.79 | HTR1A (0.58) | HTR1ADRD2HTR2ASLC6A4DRD4 | |
| Hydrochloric Acid SCHEMBL10837761 | 0.79 | DRD2 (0.61) | HTR1ADRD2HTR2ASLC6A4DRD4 | |
| SCHEMBL5467351 | 0.79 | KCNH2 (0.55) | HTR1ADRD2HTR2A | |
| SCHEMBL8420409 | 0.78 | HTR1A (0.57) | HTR1ADRD2HTR2ASLC6A4DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070185168-A1 | Piperidine derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-08-09 | — | — | US | disclosed |
| EP-1736474-A1 | PIPERIDINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185168-A1 | Piperidine derivatives | GRIN2C, GRIN1, GRIN3A | HTR1A 481/4885DRD2 96/4885HTR2A 370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.